Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors

Clinical and Vaccine Immunology

Volumn 19, Issue 7, 2012, Pages 1005-1011

  Colmenares, V ^a   Noyola, D E ^a   Monsivais Urenda A ^a   Salgado Bustamante, M ^b   Estrada Capetillo, L ^a   Gonzalez Amaro R ^a   Barandaa, L ^a  

^a School of Medicine   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CELL RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN LIKE TRANSCRIPT 2 PROTEIN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNIZATION; IN VITRO STUDY; INNATE IMMUNITY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WART VIRUS;

ADOLESCENT; ADULT; ANTIGENS, CD; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTES; MONOCYTES; PAPILLOMAVIRUS VACCINES; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 84863550449     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00043-12     Document Type: Article

References (30)

1. Antrobus RD, et al. 2005. Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules. J. Infect. Dis. 191:1842-1853. (Pubitemid 40705391)
2. Arreygue-Garcia NA, et al. 2008. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 8:16. doi:10.1186/1471-2407-8-16.
3. Carrington M, et al. 2005. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201:1069-1075. (Pubitemid 40524675)
4. Cutts FT, et al. 2007. Human papillomavirus and HPV vaccines: a review. Bull. World Health Org. 85:719-726. (Pubitemid 47416724)
5. Doníz-Padilla L, et al. 2011. Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease. Eur. J. Endocrinol. 165:129-136.
6. Frazer IH. 2009. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384:410-414.
7. Garcia-Iglesias T, et al. 2009. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer. 9:186. doi:10.1186/1471-2407-9-186.
8. Gumá M, et al. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664-3671.
9. Hasan UA, et al. 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178:3186-3197. (Pubitemid 46333201)
10. Ince MN, et al. 2004. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology 112:531-542. (Pubitemid 39061477)
11. Kanodia S, Fahey L, Kast W. 2007. Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 7:79-89. (Pubitemid 46345510)
12. Lee SJ, et al. 2001. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J. Immunol. 167:497-504.
13. Merlo A, et al. 2001. CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis. Infect. Immun. 69:6022-6029. (Pubitemid 32885161)
14. Monsiváis-Urenda A, et al. 2007. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J. Autoimmun. 29:97-107.
15. Monsiváis-Urenda A, et al. 2010. Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur. J. Immunol. 40:1418-1427.
16. Nakajima H, et al. 2003. Transcriptional regulation of ILT family receptors. J. Immunol. 171:6611-6620. (Pubitemid 37532093)
17. Paust S, von Andrian UH. 2011. Natural killer cell memory. Nat. Immunol. 12:500-508.
18. Prod'homme V, et al. 2007. The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. J. Immunol. 178:4473-4481. (Pubitemid 46492399)
19. Renoux VM, et al. 2011. Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur. J. Immunol. 41:3240-3252.
20. Sayós J, Martínez-Bariocanal A, Kitzig F, Bellón T, López-Botet M. 2004. Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. Biochem. Biophys. Res. Commun. 324:640-647.
21. Scott M, Nakagawa M, Moscicki AB. 2001. Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. 8:209-220. (Pubitemid 32217046)
22. Seliger B, Abken H, Ferrone S. 2003. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol. 24:82-87. (Pubitemid 36120644)
23. Shah W, et al. 2011. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+ FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell. Mol. Immunol. 8:59-66.
24. Stanley M. 2008. Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109(Suppl. 2):S15-S21. (Pubitemid 351636109)
25. Suzich JA, et al. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U. S. A. 92:11553-11557. (Pubitemid 26014152)
26. Textor S, et al. 2008. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int. J. Cancer 123:2343-2353.
27. Wang SS, et al. 2002. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J. Infect. Dis. 186:598-605. (Pubitemid 34925531)
28. Wang SS, et al. 2001. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J. Infect. Dis. 184:1310-1314. (Pubitemid 33055576)
29. Yang R, et al. 2005. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J. Virol. 79:6741-6750. (Pubitemid 40677305)
30. Zheng N, et al. 2011. Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. Tissue Antigens 77:218-224.